Clinical Trial Update: A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Participants With Locally Recurrent or Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study comparing paclitaxel plus GDC-0941 versus paclitaxel with placebo in locally recurrent or metastatic breast cancer; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• GDC-0941 (GDC-0941)
• Taxol (paclitaxel)

Snippet

Sponsor: Genentech, Inc. | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED